Stockscreener 앱 받기
5.30
1.15%
0.06
시간 외 거래:
5.40
0.10
+1.89%
전일 마감가:
$5.24
열려 있는:
$5.24
하루 거래량:
3.23M
Relative Volume:
0.92
시가총액:
$471.72M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+12.77%
1개월 성능:
+2.12%
6개월 성능:
+35.90%
1년 성능:
+184.95%
1일 변동 폭
$5.20
$5.395
1주일 범위
$4.7535
$5.74
52주 변동 폭
$1.67
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.30 | 475.28M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Traders Consider Averaging Down in aTyr Pharma Inc.Entry Alert Based on Volume Spikes Detected - metal.it
Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma - TipRanks
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
3 Innovation Stocks With Parabolic Upside Potential - AOL.com
3 Innovation Stocks With Parabolic Upside Potential - The Motley Fool
aTyr Pharma Reports Q2 2025 Financial Results - TipRanks
Atyr Pharma: Q2 Earnings Snapshot - Stamford Advocate
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma reports Q2 EPS (22c), consensus (18c) - TipRanks
Major Phase 3 Milestone: aTyr's Pulmonary Sarcoidosis Drug Shows Promise as 268-Patient Trial Wraps Up - Stock Titan
aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks
aTyr Pharma stock awaits key Phase 3 trial results, Cantor Fitzgerald maintains Overweight rating - Investing.com Canada
aTyr Pharma stock rating reiterated by Cantor Fitzgerald ahead of trial data - Investing.com Canada
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth? - Yahoo Finance
Should I hold or sell aTyr Pharma Inc. stock in 2025Free Trading Psychology Coaching - Jammu Links News
Is it the right time to buy aTyr Pharma Inc. stockOutstanding risk-reward balance - Jammu Links News
What drives aTyr Pharma Inc. stock priceDiscover stocks with explosive growth potential - Jammu Links News
What are the technical indicators suggesting about aTyr Pharma Inc.Invest confidently with professional market insights - Jammu Links News
What analysts say about aTyr Pharma Inc. stockAchieve exceptional returns with expert guidance - Jammu Links News
What makes aTyr Pharma Inc. stock price move sharplyDiscover high-impact stocks for your portfolio - Jammu Links News
How does aTyr Pharma Inc. generate profit in a changing economyMaximize your gains with expert trading tips - Jammu Links News
Is aTyr Pharma Inc. stock overvalued or undervaluedBuild a portfolio that withstands market volatility - Jammu Links News
What institutional investors are buying aTyr Pharma Inc. stockCapitalize on fast-moving stock opportunities - Jammu Links News
Is aTyr Pharma Inc. in Accumulation Phase NowExpert Verified Stock Trade Ideas Backed by Data - metal.it
Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here? - Barchart.com
Price Channel Expanding on aTyr Pharma Inc.’s ChartReal Time Stock Movement Analysis Indicates Breakout - metal.it
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), aTyr Pharma (ATYR) and HCA Healthcare (HCA) - The Globe and Mail
Price Consolidation Hints at Upcoming Move in aTyr Pharma Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Wyckoff Accumulation Phase Possible in aTyr Pharma Inc.Entry Plan for Oversold Reversal Stocks Released - metal.it
Will aTyr Pharma Inc. Recover After Recent DeclineMarket Momentum Signal Generator Shows Trends - metal.it
Published on: 2025-07-29 07:01:04 - beatles.ru
aTyr Pharma Inc. Breakout Confirmed by Volume MetricsWatchlist for Smart Swing Trading Updated - metal.it
aTyr Pharma Stock Faces Market Scrutiny Amid Financial Challenges - StocksToTrade
aTyr Pharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Entry and Exit Point Tips From Traders - metal.it
What is aTyr Pharma Inc. company’s growth strategyMaximize returns with data-driven strategies - Jammu Links News
What are aTyr Pharma Inc. company’s key revenue driversGet daily updates on the hottest stocks - Jammu Links News
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):